natgillin/translations-raw huggingface dataset:
People who are not taking Siklos and in particular pregnant women should avoid being in contact with hydroxycarbamide.
Ljudje, ki jemljejo zdravilo Siklos, in še posebno nosečnice, se morajo izogibati stiku s hidroksikarbamidom.
People who did not respond to the first dose can be given a second dose after at least four weeks.
Osebe, ki se niso odzvale na prvi odmerek,lahko prejmejo drugi odmerek po najmanj štirih tednih.
People who find it hard to take capsules can use a liquid form of this medicine (oral suspension).
Bolniki, ki težko požirajo kapsule lahko uporabijo tekočo obliko tega zdravila (peroralno suspenzijo).
People who have not been previously vaccinated against smallpox should receive two 0.5 ml doses, with the second dose given no less than 28 days after the first.
Posamezniki, ki še niso bili cepljeni proti črnim kozam, morajo prejeti dva odmerka po 0,5 ml, pri čemer je drugi odmerek treba dati najmanj 28 dni po prvem odmerku.
People who might get this type of infection include those having chemotherapy, those who have had a transplant and those whose immune systems are weak. suspected fungal infections if you have a fever and a low white cell count that have not improved on treatment with an antibiotic.
Med tiste, ki bi lahko oboleli za to okužbo, spadajo bolniki, ki prejemajo kemoterapijo, bolniki po transplantaciji ali tisti, ki imajo oslabel imunski sistem. verjetnih glivnih okužb, če imate zvišano telesno temperaturo in nizko število belih krvnih celic, ki se ne izboljšata po zdravljenju z antibiotiki.
People with a known hypersensitivity to any of the active ingredients or excipients should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na katerokoli zdravilno učinkovino, naj se izogibajo stiku z zdravilom.
People with a known hypersensitivity to fluoxetine should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na fluoksetin naj se izogibajo stika z veterinarskim zdravilom.
People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections).
Boniki z napredovano okužbo s HIV (AIDS-om) imajo oslabel imunski sistem, zato je pri njih večja verjetnost, za nastanek resnih okužb (oportunističnih okužb).
People with diabetes sometimes get symptoms of low blood sugar (also called hypoglycaemia).
Ljudje s sladkorno boleznijo včasih dobijo simptome znižanega krvnega sladkorja (imenuje se tudi hipoglikemija).
People with Gaucher disease have low levels of an enzyme called acid -glucosidase.
Ljudje z Gaucherjevo boleznijo imajo nizko raven encima, ki se imenuje kisla -glukozidaza.
People with hypersensitivity to telmisartan or other sartans/ARBs should avoid contact with the veterinary medicinal product.
Osebe s preobčutljivostjo na telmisartan ali druge sartane/ARB naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with kidney problems
Ljudje s težavami ledvic
People with kidney problems
Ljudje, ki imajo težave z ledvicami
People with known allergies to the phenylpyrazole class of compounds or any of the excipients should avoid contact with the product.
Osebe z znano preobčutljivostjo na spojine iz skupine fenilpirazolov ali na katerokoli pomožno snov naj se izogibajo stiku z zdravilom.
People with known hypersensitivity (allergy) to similar antibiotics (macrolide class) should avoid contact with ZACTRAN.
Osebe z znano preobčutljivostjo za (alergijo na) sorodne antibiotike (iz skupine makrolidov) naj se izogibajo stiku z zdravilom ZACTRAN.
People with known hypersensitivity to any of the ingredients should avoid contact with the product.
Osebe z znano preobčutljivostjo za katero koli sestavino naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to any of the ingredients should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na katero od sestavin naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to any of the ingredients should avoid contact with the veterinary medicine.
Osebe z znano preobčutljivostjo na katero od sestavin naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to benazepril or spironolactone should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na benazepril ali spironolakton naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to clomipramine should administer the product with caution.
Osebe z znano preobčutljivostjo na klomipramin naj bodo pri dajanju zdravila zelo pazljive.
People with known hypersensitivity to dinotefuran, pyriproxyfen or dimethyl sulfoxide should avoid contact with this veterinary medicinal product.
Osebe z znano preobčutljivostjo na dinotefuran, piriproksifen ali dimetil sulfoksid, naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to fenbendazole should avoid contact with the veterinary medicinal product.
Ljudje z znano preobčutljivostjo na fenbendazol se morajo izgibati stiku s tem zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to indoxacarb and/or permethrin should avoid contact with this product.
Ljudje z znano preobčutljivostjo na indoksakarb in/ali permetrin naj ne uporabljajo tega zdravila.
People with known hypersensitivity to indoxacarb should not use this product.
Ljudje z znano preobčutljivostjo na indoksakarb naj ne uporabljajo tega zdravila.
People with known hypersensitivity to masitinib should not handle the product.
Osebe z znano preobčutljivostjo na masitinib naj ne rokujejo z zdravilom.
People with known hypersensitivity to meloxicam should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to monensin or any of the excipients should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na monenzin ali katero od pomožnih snovi naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to non-steroidal anti- inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (Non-Steroidal Anti-Inflammatory Drugs, NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila (NSAR) naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za NSAR naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila ( NSAID ) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila ( NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za NSAID naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to pegbovigrastim should avoid contact with the product.
Osebe z znano preobčutljivostjo na pegbovigrastim naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to penicillins and cephalosporins should avoid contact with this veterinary medicinal product.
Osebe z znano preobčutljivostjo na ceftiofur naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to prednisolone or any of the excipients should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na prednizolon ali katero koli pomožno snov naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to prednisolone or any of the excipients should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo za prednizolon ali katero koli pomožno snov naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to quinolones should avoid any contact with the product.
Osebe z znano preobčutljivostjo na kinolone naj se izogibajo direktnemu stiku z zdravilom.
People with known hypersensitivity to quinolones should avoid any contact with the product.
Osebe z znano preobčutljivostjo na kinolone naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to quinolones should avoid any contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na kinolone naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to the active substance or any of the excipients should administer the product with caution.
Osebe z znano preobčutljivostjo na zdravilno učinkovino ali katerokoli pomožno snov morajo zdravilo za uporabo v veterinarski medicini dajati previdno.
People with known hypersensitivity to the macrolide class should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na makrolidne antibiotike naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
People with known hypersensitivity to the prednisolone or any of the excipients should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na prednizolon ali katero koli pomožno snov naj se izogibajo stiku z zdravilom.
People with known hypersensitivity to valnemulin should administer the product with caution.
Osebe z znano preobčutljivostjo na valnemulin naj zdravilo uporabljajo previdno.
People with known hypersensitivity to valnemulin should administer the veterinary medicinal product with caution.
Osebe z znano preobčutljivostjo na valnemulin morajo biti previdne pri dajanju zdravila za uporabo v veterinarski medicini.
People with liver problems
bolniki, ki imajo težave z jetri
People with metastatic breast cancer who received Abraxane where another therapy had failed, were more likely to experience a reduction in tumour size, and lived longer than people who took an alternative therapy.
Pri ljudeh z metastatskim rakom dojk, ki so po neuspehu drugačne oblike zdravljenja prejemali zdravilo Abraxane, je pogosteje prišlo do zmanjšanja velikosti tumorja, živeli pa so dlje kot bolniki, ki so uporabljali alternativno obliko zdravljenja.
People with more serious rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting lymphoma (a kind of cancer that affects the lymph system), and leukaemia (a kind of cancer that affects the blood and bone marrow).
Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom (vrsto raka, ki prizadene limfatični sistem) in levkemijo (vrsto raka, ki prizadene kri in kostni mozeg).
People with more serious rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting lymphoma (a kind of cancer that affects the lymph system), and leukemia (a kind of cancer that affects the blood and bone marrow).
Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom (vrsto raka, ki prizadene limfatični sistem) in levkemijo (vrsto raka, ki prizadene kri in kostni mozeg).
People with MPS VI disease have either a low level, or no level, of an enzyme called
Osebe z MPS VI imajo bodisi nizko vrednost ali pa sploh nimajo encima, ki se imenuje
People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the veterinary medicinal product with caution.
Osebe z občutljivo kožo ali znano alergijo na tovrstna zdravila za uporabo v veterinarski medicini naj s tem zdravilom za uporabo v veterinarski medicini ravnajo previdno.
People with severe kidney problems
bolniki, ki imajo hude težave z ledvicami
People with type 2 diabetes either don’t make enough insulin (a hormone that controls blood sugar levels), or don’t respond normally to the insulin their body makes.
Pri bolnikih s sladkorno boleznijo tipa 2 telo ne proizvaja dovolj insulina (hormon, ki nadzira vrednost krvnega sladkorja) ali pa se telo na insulin, ki nastane v telesu, ne odzove normalno.
people)
10.000 bolnikov):
peptic ulcer reactivated, dry mouth gastrointestinal disorder, constipation
ponovitev peptičnega ulkusa, suha usta, prebavne motnje, zaprtje
peptic ulcer reactivated, gastrointestinal disorder, constipation, dry mouth
ponovitev peptičnega ulkusa, prebavne motnje, zaprtje, suha usta
Peptic ulcer, pancreatitis
želodčni čir, pankreatitis
Peptic ulcer, retching, upper gastrointestinal haemorrhage
peptična razjeda, siljenje na bruhanje, krvavitev v zgornjih prebavilih
Per 0.1 ml dose
na 0,1 ml odmerka
per 0.2 ml dose
na 0,2 ml odmerek
per 0.2 ml dose
na 0,2-ml odmerek
per 0.25 ml
odmerku po 0,25 ml
Per 1 ml dose of the reconstituted product:
V odmerku po 1 ml rekonstituiranega zdravila:
Per 1 ml dose:
Na odmerek (1 ml):
Per 1 ml dose:
V odmerku po 1 ml:
Per 1 ml dose:
Vsak odmerek po 1 ml vsebuje:
Per 1 ml dose: Active substance:
V odmerku po 1 ml: Zdravilna učinkovina:
Per 1 ml dose: rabies recombinant canarypox virus (vCP65)
V 1 odmerku (1 ml): Rekombinantni poxvirus (vCP65)
Per 1-ml dose: Canine herpesvirus (F205 strain) antigens ...............................................
V 1-ml odmerku: antigeni pasjega herpesvirusa (sev F205) ............................................
Per 2 ml dose:
V odmerku 2 ml:
Per 2 ml:
En odmerek po 2 ml vsebuje:
per day
/dan
per day
dan
Per day
Dnevno
Per dose (1 ml):
Na odmerek (1 ml):
Per dose of 0.2 ml vaccine:
V odmerku po 0,2 ml cepiva:
Per dose of 0.5ml:
V odmerku po 0,5 ml:
Per dose of 1 ml
V odmerku po 1 ml:
Per dose of 1 ml (single dose syringe):
1 odmerek po 1 ml (enoodmerna brizga) vsebuje:
Per dose of 1 ml:
1 odmerek (1 ml) vsebuje:
Per dose of 1 ml:
V odmerku po 1 ml :
Per dose of 2 ml
V odmerku 2 ml
Per dose of 2 ml
V odmerku 2 ml:
Per dose of 2 ml:
V odmerku 2 ml
Per dose of 2 ml:
V odmerku po 2 ml:
per dose of 2 ml: adhesins:
V 2 ml odmerku:
per dose of 2 ml: coli adhesin F4 (F4ab, F4ac, F4ad), at least….2.1 SA.U*
V 2 ml odmerku: coli adhezin F4 (F4ab, F4ac, F4ad), najmanj 2,1 SA.U
Per dose of two ml:
V odmerku po dva ml:
Per dose:
V enem odmerku:
per patient weight
bolnikovo telesno maso
Per –Protocol (PP) Population (N=39)
Populacija po protokolu (Per Protocol – PP, N = 39)
per-dose frequency per-subject frequency
pogostnost na odmerek pogostnost na preiskovanca
Per-protocol
Po protokolu
Perampanel as adjunctive therapy in patients 12 years of age and older with idiopathic generalised epilepsy experiencing primary generalised tonic-clonic seizures was established in a multicenter, randomised, double-blind, placebo-controlled study (Study 332).
Perampanel kot pomožno zdravljenje pri bolnikih starosti 12 let in več z idiopatsko generalizirano epilepsijo, ki so imeli primarne generalizirane napade s tonično-kloničnimi krči, so proučili v multicentrični, randomizirani, dvojno slepi, s placebom kontrolirani študiji (študija 332).
Perampanel at a dose up to 8 mg/day has been shown to be effective in primary generalised tonic- clonic seizures.
Perampanel v odmerku do 8 mg/dan se je izkazal za učinkovitega pri primarnih generaliziranih napadih s tonično-kloničnimi krči.
Perampanel dosing for patients with mild and moderate impairment should not exceed 8 mg.
Odmerek perampanela naj pri bolnikih z blago do zmerno okvaro ne preseže 8 mg.
Perampanel is a first-in-class selective, non-competitive antagonist of the ionotropic α-amino-3- hydroxy-5-methyl-4-isoxazolepopionic acid (AMPA) glutamate receptor on post-synaptic neurons.
Perampanel je prvi predstavnik novega razreda zdravil in je selektiven, nekompetitiven antagonist ionotropnih receptorjev glutamat α-amino-3-hidroksi-5-metil-4-izoksazolepopionske kisline (AMPA) na postsinaptičnih nevronih.
Perampanel is a first-in-class selective, non-competitive antagonist of the ionotropic α-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons.
Perampanel je prvi predstavnik novega razreda zdravil in je selektiven, nekompetitiven antagonist ionotropnih receptorjev glutamat α-amino-3-hidroksi-5-metil-4-izoksazolepropionske kisline (AMPA) na postsinaptičnih nevronih.
Percent
Odstotek
Percent (n) of patients who withdrew due to inadequate analgesia Hours 3-24
Odstotek (n) bolnikov, ki so prenehali sodelovati zaradi nezadostne analgezije po 3 do 24 urah
Percent 99mTc-depreotide: 100 - (A + B).
Odstotni delež 99mTc-depreotida: 100 – (A+B).
Percent Change BSAe (%) mean± SD
odstotna sprememba BSAe (%) povprečje± SD
Percent change* n=406
Sprememba v odstotkih* n = 406
Percent HIV-RNA
Odstotek HIV-RNA
Percent HIV-RNA < 400 copies/ml (95 % CI)
HIV-RNA > 100.000 kopij/ml
Percent HIV-RNA < 400 copies/ml (95 % CI)
Odstotek HIV-RNA < 400 kopij/ml (95-odstotni IZ)
Percent HIV-RNA < 50 copies/ml
Odstotek HIV-RNA < 50 kopij/ml
Percent HIV-RNA < 50 copies/ml (95 % CI)
Odstotek HIV-RNA < 50 kopij/ml (95 % IZ)
Percent of adult patients receiving Highly Emetogenic Chemotherapy responding by treatment group and phase — Cycle 1
Odstotek odraslih bolnikov, ki so prejemali zelo emetogeno kemoterapijo, z odzivom po zdravljenih skupinah in fazi – 1. ciklus
Percent of adult patients receiving Highly Emetogenic Chemotherapy who remain emesis free over time – Cycle 1
Odstotek odraslih bolnikov, ki so prejemali zelo emetogeno kemoterapijo, pri katerih se bruhanje ne pojavi, glede na čas – 1. ciklus
Percent of adult patients responding by treatment group and phase for Study 2 – Cycle 1 Moderately Emetogenic Chemotherapy
Odstotek odraslih bolnikov z odzivom po zdravljenih skupinah in fazi v študiji 2 – 1. ciklus Zmerno emetogena kemoterapija
Percent of adult patients responding by treatment group and phase — Cycle 1 Moderately Emetogenic Chemotherapy
Odstotek odraslih bolnikov z odzivom po zdravljenih skupinah in fazi – 1. ciklus Zmerno emetogena kemoterapija
Percent of Patients
Odstotek bolnikov
Percent of patients achieving corticosteroid-free clinical remission at week 26, SONIC
Odstotek bolnikov, ki so dosegli klinično remisijo brez jemanja kortikosteroidov v 26. tednu, SONIC
Percent of Patients Placebo Enbrela
Odstotek bolnikov Placebo Zdravilo Enbrela
Percent of patients receiving Highly Emetogenic Chemotherapy responding by treatment  group and phase — Cycle 1
Odstotek bolnikov, ki so prejemali zelo emetogeno kemoterapijo z odzivom po zdravljenih skupinah in fazi – 1. ciklus
Percent of patients receiving Moderately Emetogenic Chemotherapy responding by  treatment group and phase
Odstotek bolnikov, ki so prejemali zmerno emetogeno kemoterapijo z odzivom po  zdravljenih skupinah in fazi
Percent of patients receiving Moderately Emetogenic Chemotherapy who remain emesis free over time
Odstotek bolnikov, ki so prejemali zmerno emetogeno kemoterapijo, pri katerih se bruhanje ne pojavi, glede na čas
Percent of patients with no worsening by BILAG
Odstotek bolnikov brez poslabšanja indeksa BILAG
Percent of post-operative adults responding by treatment group Combined results from 2 Phase III trials
Odstotek odraslih z odzivom po operaciji glede na skupino zdravljenja Kombinirani rezultati iz 2 preskušanj faze III
Percent Predicted FVC
predvideni odstotek FVC
Percent predicted FVC (%)1
predvideni odstotek FVC (%)1
Percent reduction
Odstotno zmanjšanje
Percent reduction in OCS from baseline (weeks 20-24)
Odstotno zmanjšanje PKS od izhodišča (20. - 24. teden)
Percent reduction Rate ratio (95% CI)
Odstotno zmanjšanje Razmerje deležev (95 % IZ)
Percent survival at 12 months (95% CI)
Odstotek preživetja po 12 mesecih (95 % IZ)
Percent with
Odstotek z
Percent with EDSS ≥ 3.5
Odstotek z EDSS ≥ 3,5
Percentage (%) of Subjects Losing ≥5% and ≥10% of Body Weight from Baseline to Week 56 in Phase 3 Studies NB-301, NB-302, and NB-304 and from Baseline to Week 28 in Phase 3 Study NB-303
Odstotek (%) preiskovancev, ki so zmanjšali telesno maso za ≥5 % in ≥10 % od izhodiščne vrednosti do 56. tedna v študijah 3. faze NB-301, NB-302 in NB-304 ter od izhodiščne vrednosti do 28. tedna v študiji 3. faze NB-303
Percentage ACR improvement
Odstotek izboljšanja ACR
Percentage Change in Liver Volume MN (%)
Odstotek spremembe v prostornini jeter MN (%)
Percentage Change in Liver Volume MN (%) (secondary endpoint)
Odstotek spremembe v prostornini jeter MN (%) (sekundarna končna točka)
Percentage Change in Platelet Count (%)
Odstotek spremembe v številu trombocitov (%)
Percentage Change in Platelet Count (%) (secondary endpoint)
Odstotek spremembe v številu trombocitov (%) (sekundarna končna točka)
Percentage Change in Spleen Volume MN (%) (primary endpoint)
Odstotek spremembe prostornine vranice MN (%) (primarna končna točka)
Percentage Change in Spleen Volume MN (%)*
Odstotek spremembe v prostornini vranice MN (%)